Tissue researchCat. DHN-P-0157
BPC-157
What this compound is
BPC-157 is a synthetic pentadecapeptide — fifteen residues, sequence GEPPPGKPADDAGLV — whose sequence is a partial fragment of a protein first isolated from human gastric juice. Supplied as a lyophilised acetate salt for in vitro laboratory investigation.
- Form
- Lyophilised powder
- Purity
- ≥98.0% (HPLC, 214 nm)
- Storage
- −20 °C, desiccated, protected from light, inert atmosphere
- Made in
- the United States
More in Tissue researchSee the class →
Questions about this line
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide — fifteen residues, sequence GEPPPGKPADDAGLV — whose sequence is a partial fragment of a protein first isolated from human gastric juice. Supplied as a lyophilised acetate salt for in vitro laboratory investigation.
What arrives with an order of BPC-157?
Each unit is supplied in its labelled presentation. The documentation centre lists what accompanies an order in full.
How is BPC-157 stored?
Unopened, at −20 °C, desiccated, protected from light, inert atmosphere.
Which sizes and quantities are sold?
In boxes of ten vials, at 5mg, 10mg, 2mg. This line is supplied by the box and is not split into single vials. Twenty-five vials or more are quoted on enquiry.
Where can BPC-157 be delivered?
To United States delivery addresses. Every order is checked against this compound’s own destination list before it is recorded; the full position is on the shipping and destinations page.
Specification
Chemical identity, sequence, form and handling — the full record for this line
| Chemical name | L-Valine, glycyl-L-α-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-α-aspartyl-L-α-aspartyl-L-alanylglycyl-L-leucyl- |
|---|---|
| Synonyms | Pentadecapeptide BPC 157; PL 14736; Body Protection Compound-157 |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.56 g·mol⁻¹ (average, free base) |
| Sequence (one-letter) | GEPPPGKPADDAGLV |
| Sequence (three-letter) | H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH |
| Residues | 15 |
| Counter-ion | Trifluoroacetate (TFA) salt |
| Purity specification | ≥98.0% (HPLC, 214 nm) |
| Physical form | Lyophilised powder |
| Appearance | White to off-white solid |
| Solubility | Water; sterile distilled water suggested for stock preparation |
| Storage | −20 °C, desiccated, protected from light, inert atmosphere |
| Shipping condition | Ambient; lyophilisate stable for short-duration transit |
| Retest interval | 24 months from date of manufacture |
| Current lot | Assigned at dispatch and recorded against the order |
Documentation
Lot identification, hazard information and datasheet for this line
Safety Data Sheets. The required language set below is derived from this compound's destination allow-list, so opening a new destination adds its language here automatically.
Compliance and supply record
The formal record for this line — hazard labelling, traceability, supply controls, citations and terms of supply
Regulatory status and supply controls
Statement of position. This compound holds no marketing authorisation as a medicinal product in any EU/EEA Member State or in the United Kingdom. It is not offered, and may not be used, for any human or veterinary application. Every order carries a research-use declaration signed by name, is screened against sanctions and embargo lists, and is checked line by line against the destination policy published for the compound.
Destinations served for this compound — the published list operates as an allow-list. Destinations not listed are not served.
Destinations not served for this compound — determined by destination-state medicines and anti-doping law, not by carrier availability:
| Destination policy legal sign-off | Counsel sign-off pending — the allow-list is not asserted until obtained |
|---|---|
| Quantity ceiling | 50 mg per verified account per rolling 30 days |
Hazard classification and labelling — CLP Regulation (EC) 1272/2008
| Pictograms | Assessment pending — no classification asserted |
|---|---|
| Signal word | Assessment pending |
| Hazard statements (full text) | Assessment pending |
| Supplemental (EUH) | Assessment pending |
| Precautionary statements (full text) | Assessment pending |
| UFI | Assigned on classification — required for classified mixtures |
| C&L Inventory notification | Due on placing on the market — due within 1 month of placing on the market |
| Poison Centre notification | Due on classification as a mixture — harmonised format, mandatory since 1 January 2025 |
Product safety and traceability — Regulation (EU) 2023/988 (GPSR) Art. 19
| Manufacturer | Published before first supply (GPSR Art. 19) |
|---|---|
| Manufacturer postal address | Published before first supply |
| Manufacturer electronic address | Published before first supply |
| EU responsible economic operator | Dohrna Research Supplies Limited, 4th Floor Kingsway Palace, Triq ir-Repubblika, Valletta VLT 1115, Malta |
| Responsible operator designated | Designation not yet published |
| Responsible operator contact | safety@dohrna.com |
| Product identifier | DHN-P-0157 |
| Technical file retention | 10 years from placing on the market |
| Safety warnings | Provided in an official language of each Member State of destination. See the Documentation panel. |
Literature
Citations for this line are being curated from PubMed and are published here as author, journal and year with DOI and PMID — identifiers only.
Conditions of supply
This product is supplied for laboratory research use only, by and for qualified personnel trained in laboratory procedures and familiar with the potential hazards of the material. It is not supplied for human or veterinary use, for pharmaceutical, diagnostic or therapeutic use, or for household, food, cosmetic or agricultural use. It has not been evaluated by any medicines regulator for safety or efficacy in humans or animals.
Buyer warranty. By placing an order the Buyer represents and warrants that: (a) it is acquiring the Products in the course of a trade, business, craft or profession and not as a consumer; (b) the Products will be used solely for in vitro laboratory research; (c) the Products will not be administered to humans or animals, resold to the general public, or incorporated into any product for human or animal use; (d) the person placing the order is at least 18 years of age and is authorised to bind the Buyer; and (e) the Buyer will comply with all applicable medicines, chemicals, health-and-safety, export-control and sanctions laws in its jurisdiction.
The Buyer is responsible for determining the suitability of the product for its intended research use, for testing it, and for its safe handling, storage and disposal. Resale or onward transfer is prohibited without prior written permission.
Not supplied to this region. The destinations served for this compound are listed below. Switch region
Size
This size is despatched separately and arrives in 7 to 12 days.
The vials in this size carry the compound name, the strength and the research-use statement. They do not carry the Dohrna label.
Questions, a bigger order, or something not listed? WhatsApp the team
Ordering requirements and merchant facts
Charge will appear as: DOHRNA RESEARCH REAGENTS
Refunds and returns policy is presented in full, with acknowledgement required, before the order is confirmed.
Restricted destinations apply to this compound — see Regulatory status.
Delivery tracked and signed for. 3-D Secure 2 authentication applies to every transaction.
Often ordered together
